Author: Zacks Small Cap Research

1717273747597730 / 962 POSTS
By John Vandermosten, CFAOTCQX:DYAIREAD THE FULL DYAI RESEARCH REPORTINITIATING COVERAGEWe are initiating coverage of Dyadic International Inc. (OTCQX:DYAI) with a $4.50 price target based on our estimates for commercialization of the company’s propr ...
By John Vandermosten, CFANASDAQ:RXIIREAD THE FULL RXII RESEARCH REPORTOn October 3rd, 2018 RXi Pharmaceuticals Corp. (NASDAQ:RXII) announced it had closed its $15 million public underwriting. 3.725 million shares were issued at $0.70 per share and 17 ...
By David Bautz, PhDNASDAQ:MTFBREAD THE FULL MTFB RESEARCH REPORTBusiness UpdateMotif Bio Plc (NASDAQ:MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s le ...
By David Bautz, PhDNASDAQ:MTPREAD THE FULL MTP RESEARCH REPORTBusiness UpdateMidatech Pharma Plc (NASDAQ:MTP) is a biotechnology company with three novel drug delivery technologies that all improve bio-distribution and bio-delivery of drugs. The tech ...
By David Bautz, PhDNASDAQ:VKTXREAD THE FULL VKTX RESEARCH REPORTBusiness UpdateVK5211 Phase 2 Results Presented at ASBMR 2018 Annual MeetingOn October 1, 2018, Viking Therapeutics, Inc. (NASDAQ:VKTX) announced that results from the Phase 2 clinical t ...
By Brian Marckx, CFAOTC:PBSVREAD THE FULL PBSV RESEARCH REPORTLab Sale Improves Profitability, Further Bolsters Cash, Provides Strategic Options. Moving Price Target to $2.25/share…Pharma-bio Serv (OTC:PBSV) reported financial results for their fisca ...
By David Bautz, PhDNASDAQ:CERCREAD THE FULL CERC RESEARCH REPORTBusiness UpdateCerecor, Inc. (CERC) is a fully integrated pharmaceutical company with a diversified offering of commercial products and a development product portfolio. The commercial po ...
By John Vandermosten, CFANASDAQ:CORVCorrevio Pharma Corp. (NASDAQ:CORV) has had an exciting year for Brinavess so far in 2018. The asset was initially developed by Correvio’s predecessor company Cardiome starting in 1986 and bought by Merck for furth ...
By Brian Marckx, CFANASDAQ:EYEGREAD THE FULL EYEG RESEARCH REPORTQ2 2018 Financial Results, Operating Update…EyeGate (NASDAQ:EYEG) reported Q2 2018 financial results and provided a business update. As it relates to the financials, Q2 included additio ...
By David Bautz, PhDNASDAQ:MNOVREAD THE FULL MNOV RESEARCH REPORTBusiness UpdatePositive FDA Feedback Regarding Phase 3 ALS Development PlanOn September 25, 2018, MediciNova, Inc. (NASDAQ:MNOV) announced that the FDA provided positive feedback in rega ...
1717273747597730 / 962 POSTS